 FOSTER CITY, Calif., June 08, 2022 GLOBE NEWSWIRE -- Terns Pharmaceuticals, Inc. Terns or the Company Nasdaq: TERN, a clinical-stage biopharmaceutical company developing a portfolio of small-molecule single-agent and combination therapy candidates to address serious diseases such as non-alcoholic steatohepatitis NASH, obesity and cancer, today announced that five abstracts detailing clinical data for multiple non-alcoholic steatohepatitis NASH programs within the Companys portfolio were accepted for presentation at The International Liver CongressTM 2022 taking place June 22-26 in London, United Kingdom. The abstracts were published in the July supplement of the Journal of Hepatology. 